A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)

NCT01351415 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

485

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Interventions

DRUG: Bevacizumab
DRUG: Docetaxel
DRUG: Erlotinib
DRUG: Pemetrexed

Sponsor

Hoffmann-La Roche